Skip to main content
. 2014 Apr;3(2):156–182. doi: 10.3978/j.issn.2224-4336.2014.02.01

Table 1. Frequency, incidence, and survival of childhood cancer.

Diagnosisa Frequencyb (% of all cancer) Incidencec per million Peak age (incidence per million) 5-year survival (%)d
Year of diagnosis
1975-1979 1992-1996 2002-2006
Age 0-14 years
All cancers 100 155 62 79 83
Acute lymphoblastic leukemia (Ib) 25.8 40.0 2-3 (95.3) 63 86 90
Acute myeloid leukemia (IIb) 5.1 7.8 0-1 (19.4) 24 50 69
Non-Hodgkin lymphoma (IIb/c) 5.8 9.0 12-14 (10.5) 50 82 89
Hodgkin lymphoma (IIa) 3.7 5.8 13-14 (16.7) 84 94 97
Central nervous system (III) 21.0 32.8 1-4 (41.8) 60 71 73
Medulloblastoma (IIIc.1) 2.8 4.5 1-7 (5.9) 50 63 70
Low grade gliomae ~8.4 ~13.1 87 92 94
Neuroblastoma (IVa) 6.7 10.2 0-1 (42.7) 50 70 76
<1 year 2.2 86 90 91
1-14 years 4.4 37 57 69
Ewings’ sarcoma (VIIIc, IXd.1/d.2) 2.0 3.1 12-14 (5.5) 53 74 76
Osteosarcoma (VIIIa) 2.6 4.0 13-14 (9.3) 42 71 72
Rhabdomyosarcoma (IXa) 3.4 5.3 1-5 (7.6) 55 73 68
Wilm’s tumor (VIa.1) 4.6 7.2 1-3 (19.1) 77 93 91
Age 15-19 years
All cancers 100 211 70 79 83
Acute lymphoblastic leukemia (Ib) 8.3 17.5 34 57 70
Acute myeloid leukemia (IIb) 4.6 9.6 23 40 52
Non-Hodgkin lymphoma (IIb/c) 8.2 17.4 47 77 80
Hodgkin lymphoma (IIa) 14.4 30.3 91 95 96
Central nervous system (III) 9.6 20.3 61 76 77
Medulloblastoma (IIIc.1) 0.8 1.6 na na 71
Low grade gliomae ~3.8 ~8.1 73 88 97
Neuroblastoma (IVa) 0.2 0.4 na na na
Ewings’ sarcoma (VIIIc, IXd.1/d.2) 2.7 5.7 24 51 61
Osteosarcoma (VIIIa) 4.0 8.4 54 64 62
Rhabdomyosarcoma (IXa) 1.6 3.4 na 46 48
Wilm’s tumor (VIa.1) 0.1 0.3 na na na

a, the Roman numerals in parentheses represent the International Classification of Childhood Cancer (ICCC) site recode extended ICD-0-3/WHO 2008; b, frequency: SEER 18 registry (3); year of diagnosis: 2001-2010; % of all cancer within the age group; c, age-adjusted incidence: SEER 18 Registry (1); d, survival: SEER 18 Registry (3); na, not applicable as cohort too small (n<40); e, low grade glioma: frequency/incidence based on 40% of all CNS tumor (4-6); survival estimated from astrocytoma (IIIb) and other gliomas (IIId) of WHO grade I or II.